Literature DB >> 28728756

Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.

Ayman Samman Tahhan1, Salim S Hayek1, Pratik Sandesara1, Jamal Hajjari1, Muhammad Hammadah1, Wesley T O'Neal1, Heval M Kelli1, Ayman Alkhoder1, Nima Ghasemzadeh1, Yi-An Ko2, Hiroshi Aida1, Mohamad Mazen Gafeer1, Naser Abdelhadi1, Kareem Hosny Mohammed1, Keyur Patel1, Shipra Arya3, Jochen Reiser4, Viola Vaccarino5, Laurence Sperling1, Arshed Quyyumi6.   

Abstract

BACKGROUND AND AIMS: Circulating soluble urokinase plasminogen activator receptor (suPAR) is a marker of immune activation associated with atherosclerosis. Whether suPAR levels are associated with prevalent peripheral arterial disease (PAD) and its adverse outcomes remains unknown and is the aim of the study.
METHODS: SuPAR levels were measured in 5810 patients (mean age 63 years, 63% male, 77% with obstructive coronary artery disease [CAD]) undergoing cardiac catheterization. The presence of PAD (n = 967, 17%) was classified as carotid (36%), lower/upper extremities (30%), aortic (15%) and multisite disease (19%). Multivariable logistic and Cox regression models were used to determine independent predictors of prevalent PAD and outcomes including all-cause death, cardiovascular death and PAD-related events after adjustment for age, gender, race, body mass index, smoking, diabetes, hypertension, hyperlipidemia, renal function, heart failure history, and obstructive CAD.
RESULTS: Plasma suPAR levels were 22.5% (p < 0.001) higher in patients with PAD compared to those without PAD. Plasma suPAR was higher in patients with more extensive PAD (≥2 compared to single site) p < 0.001. After multivariable adjustment, suPAR was associated with prevalent PAD; odds ratio (OR) for highest compared to lowest tertile of 2.0, 95% CI (1.6-2.5) p < 0.001. In Cox survival analyses adjusted for clinical characteristics and medication regimen, suPAR (in the highest vs. lowest tertile) remained an independent predictor of all-cause death [HR 3.1, 95% CI (1.9-5.3)], cardiovascular death [HR 3.5, 95% CI (1.8-7.0)] and PAD-related events [HR = 1.8, 95% CI (1.3-2.6) p < 0.001 for all].
CONCLUSIONS: Plasma suPAR level is predictive of prevalent PAD and of incident cardiovascular and PAD-related events. Whether SuPAR measurement can help screen, risk stratify, or monitor therapeutic responses in PAD requires further investigation.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; CAD; Cardiovascular outcomes; PAD; PAD-Related outcomes; SuPAR

Mesh:

Substances:

Year:  2017        PMID: 28728756      PMCID: PMC5808930          DOI: 10.1016/j.atherosclerosis.2017.06.019

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  34 in total

1.  Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia.

Authors:  Anita W Rijneveld; Marcel Levi; Sandrine Florquin; Peter Speelman; Peter Carmeliet; Tom van Der Poll
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

2.  Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years.

Authors:  Shani Botha; Carla Mt Fourie; Rudolph Schutte; Jesper Eugen-Olsen; Aletta E Schutte
Journal:  Hypertens Res       Date:  2015-03-05       Impact factor: 3.872

Review 3.  Biomarkers and Genetics in Peripheral Artery Disease.

Authors:  Surovi Hazarika; Brian H Annex
Journal:  Clin Chem       Date:  2016-11-21       Impact factor: 8.327

4.  Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.

Authors:  M Persson; G Engström; H Björkbacka; B Hedblad
Journal:  Atherosclerosis       Date:  2011-11-09       Impact factor: 5.162

Review 5.  The urokinase system in the pathogenesis of atherosclerosis.

Authors:  Bianca Fuhrman
Journal:  Atherosclerosis       Date:  2011-11-16       Impact factor: 5.162

6.  Release of soluble urokinase receptor from vascular cells.

Authors:  T Chavakis; A K Willuweit; F Lupu; K T Preissner; S M Kanse
Journal:  Thromb Haemost       Date:  2001-08       Impact factor: 5.249

7.  Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization.

Authors:  Carmine Selleri; Nunzia Montuori; Patrizia Ricci; Valeria Visconte; Maria Vincenza Carriero; Nicolai Sidenius; Bianca Serio; Francesco Blasi; Bruno Rotoli; Guido Rossi; Pia Ragno
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

8.  Associations of suPAR with lifestyle and cardiometabolic risk factors.

Authors:  Shani Botha; Carla M T Fourie; Rudolph Schutte; Annamarie Kruger; Aletta E Schutte
Journal:  Eur J Clin Invest       Date:  2014-05-22       Impact factor: 4.686

9.  Participation of the urokinase receptor in neutrophil efferocytosis.

Authors:  Young-Jun Park; Gang Liu; Yuko Tsuruta; Emmanuel Lorne; Edward Abraham
Journal:  Blood       Date:  2009-04-27       Impact factor: 22.113

Review 10.  A review of the pathophysiology and potential biomarkers for peripheral artery disease.

Authors:  Smriti Murali Krishna; Joseph V Moxon; Jonathan Golledge
Journal:  Int J Mol Sci       Date:  2015-05-18       Impact factor: 5.923

View more
  10 in total

1.  Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity.

Authors:  Hershel Raff; Jonathan M Phillips; Pippa M Simpson; Steven J Weisman; Keri R Hainsworth
Journal:  Pain Rep       Date:  2020-07-22

2.  Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19.

Authors:  Alexi Vasbinder; Elizabeth Anderson; Husam Shadid; Hanna Berlin; Michael Pan; Tariq U Azam; Ibrahim Khaleel; Kishan Padalia; Chelsea Meloche; Patrick O'Hayer; Erinleigh Michaud; Tonimarie Catalan; Rafey Feroze; Pennelope Blakely; Christopher Launius; Yiyuan Huang; Lili Zhao; Lynn Ang; Monica Mikhael; Kara Mizokami-Stout; Subramaniam Pennathur; Matthias Kretzler; Sven H Loosen; Athanasios Chalkias; Frank Tacke; Evangelos J Giamarellos-Bourboulis; Jochen Reiser; Jesper Eugen-Olsen; Eva L Feldman; Rodica Pop-Busui; Salim S Hayek; Salim S Hayek; Pennelope Blakely; Hanna Berlin; Tariq U Azam; Husam Shadid; Michael Pan; Patrick O'Hayer; Chelsea Meloche; Rafey Feroze; Kishan J Padalia; Elizabeth Anderson; Danny Perry; Abbas Bitar; Rayan Kaakati; Yiyuan Huang; Lili Zhao; Jochen Reiser; Beata Samelko; Alex Hlepas; Priya P Patel; Xuexiang Wang; Jesper Eugen-Olsen; Izzet Altintas; Marius Stauning; Morten Baltzer Houlind; Mette B Lindstrøm; Hejdi Gamst-Jensen; Line Jee Hartmann; Jan O Nehlin; Thomas Kallemose; Imran Parvaiz; Christian Rasmussen; Ove Andersen; Jens Tingleff; Evangelos J Giamarellos-Bourboulis; Maria-Evangelia Adami; Nicky Solomonidi; Maria Tsilika; Maria Saridaki; Vasileios Lekakis; Sven H Loosen; Tom Luedde; Verena Keitel; Athanasios Chalkias; Eleni Arnaoutoglou; Ioannis Pantazopoulos; Eleni Laou; Konstantina Kolonia; Anargyros Skoulakis; Frank Tacke; Pinkus Tober-Lau; Raphael Mohr; Florian Kurth; Leif Erik Sander; Christoph Jochum
Journal:  Diabetes Care       Date:  2022-03-01       Impact factor: 19.112

3.  Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.

Authors:  Clemens Höbaus; Martin Ursli; Sarah Mohammed Yussef; Thomas Wrba; Renate Koppensteiner; Gerit-Holger Schernthaner
Journal:  Vasc Med       Date:  2021-01-15       Impact factor: 3.239

Review 4.  Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease.

Authors:  Dimitrios Velissaris; Nicholas Zareifopoulos; Ioanna Koniari; Vasilios Karamouzos; Dimitris Bousis; Andreas Gerakaris; Christina Platanaki; Nicholas Kounis
Journal:  J Clin Med Res       Date:  2021-03-19

5.  RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes.

Authors:  Eun Young Kim; Stuart E Dryer
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-06-22       Impact factor: 6.633

6.  Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.

Authors:  Salim S Hayek; Jasmin Divers; Mohamad Raad; Jianzhao Xu; Donald W Bowden; Melissa Tracy; Jochen Reiser; Barry I Freedman
Journal:  J Am Heart Assoc       Date:  2018-05-01       Impact factor: 5.501

7.  A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure.

Authors:  Iziah E Sama; Rebecca J Woolley; Jan F Nauta; Simon P R Romaine; Jasper Tromp; Jozine M Ter Maaten; Peter van der Meer; Carolyn S P Lam; Nilesh J Samani; Leong L Ng; Marco Metra; Kenneth Dickstein; Stefan D Anker; Faiez Zannad; Chim C Lang; John G F Cleland; Dirk J van Veldhuisen; Hans L Hillege; Adriaan A Voors
Journal:  Eur J Heart Fail       Date:  2020-04-03       Impact factor: 15.534

8.  Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease.

Authors:  Ahmed Al-Badri; Ayman Samman Tahhan; Nabil Sabbak; Ayman Alkhoder; Chang Liu; Yi-An Ko; Viola Vaccarino; Afif Martini; Arianna Sidoti; Cydney Goodwin; Bahjat Ghazzal; Agim Beshiri; Gillian Murtagh; Puja K Mehta; Arshed A Quyyumi
Journal:  J Am Heart Assoc       Date:  2020-04-17       Impact factor: 5.501

9.  Deficiency of Urokinase Plasminogen Activator May Impair β Cells Regeneration and Insulin Secretion in Type 2 Diabetes Mellitus.

Authors:  Chung-Ze Wu; Shih-Hsiang Ou; Li-Chien Chang; Yuh-Feng Lin; Dee Pei; Jin-Shuen Chen
Journal:  Molecules       Date:  2019-11-20       Impact factor: 4.411

10.  Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease.

Authors:  Anurag Mehta; Shivang R Desai; Yi-An Ko; Chang Liu; Devinder S Dhindsa; Aditi Nayak; Ananya Hooda; Mohamed A Martini; Kiran Ejaz; Laurence S Sperling; Jochen Reiser; Salim S Hayek; Arshed A Quyyumi
Journal:  J Am Heart Assoc       Date:  2020-02-22       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.